智通财经APP获悉，周一，Cassava Sciences (SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。

Investing.com -- 专注于阿尔茨海默病治疗的生物技术公司Cassava Sciences, Inc.披露，其用于研究simufilam这种实验性药物的三期临床试验ReThink-ALZ未能达到预期目标。

，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示 ，周一，Cassava Sciences(SAVA.US)股价暴跌，截至发稿，该股跌超84%，报4.06美元。该公司表示，其simufilam治疗轻度至中度阿尔茨海默症的3期ReThink-ALZ研究的初步结果没有达到预先设定的共同主要终点、次要终点和探索性生物标志物终点。 该 ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Following the disappointing results, Cassava stated it would halt a second late-stage trial of simufilam, as well as its open ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...